Insider Purchases: Inside the Buy
Tag: GIST

Cogent Biosciences (COGT): The Biotech with a Plan, a Billion Cells, and a Bezuclastinib
Insiders are buying, trials are working, and Cogent just raised $230M. Meet bezuclastinib—the biotech drug with a Marvel name and real potential. 🧬💥
Tags:
Bezuclastinib,
Biotech Stocks,
Clinical Trials,
COGT,
Cole Pinnow,
Fairmount Funds,
Funanc1al Insider Series,
Funanc1alBiotech,
Funanc1alEdge,
Funanc1alFinance,
Funanc1alFun,
Funanc1alHealth,
Funanc1alHumor,
Funanc1alInsiders,
Funanc1alInsiderSeries,
Funanc1alInvesting,
Funanc1alPharma,
Funanc1alStocks,
GIST,
Insider Buying,
Speculative Plays,
Systemic Mastocytosis
Quick links
Search
Privacy Policy
Refund Policy
Shipping Policy
Terms of Service
Contact us
About us
FUNanc!al distills the fun in finance and the finance in fun, makes news personal, and helps all reach happiness.